Recurrent Adrenal Cortical Carcinoma
2 clinical trials · Condition
◉ Watch Recurrent Adrenal Cortical Carcinoma
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer (NCT06900595) | National Cancer Institute (NCI) | 2026-02-22 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (NCT02867592) | National Cancer Institute (NCI) | 2017-05-18 |
Track Recurrent Adrenal Cortical Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.